Science Explorer Interactive view Map
Company · Newark · United States

CymaBay Therapeutics (United States)

cymabay.comROR OpenAlex
Research works
12
▲ 7% vs 2013–17
Citations
192
15.4 per fractional work
Top-10% rate
28.6%
record average 16.5%
Open access
50%
world 28%

Not ranked overall: CymaBay Therapeutics (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 5.02× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 4.44× its world share, 0 worksImmunology and Micro…Pharmacology, Toxicology and Pharmaceutics: 0.99× its world share, 0 worksPharmacology, Toxico…Engineering: 0.23× its world share, 0 worksEngineeringMedicine: 3.35× its world share, 3 worksMedicineSocial Sciences: 0.04× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.0×. Every wedge is a field page.

Which research topics does CymaBay Therapeutics (United States) publish most on?

By volume in 2022–2025: Liver Disease Diagnosis and Treatment, Drug Transport and Resistance Mechanisms, Liver Diseases and Immunity and Cancer Research and Treatments.

Liver Disease Diagnosis …1Liver Disease Diagnosis and Treatment: 1 fractional worksDrug Transport and Resistance Mechanisms: 1 fractional worksLiver Diseases and Immunity: 0 fractional worksCancer Research and Treatments: 0 fractional worksPediatric Hepatobiliary Diseases and Treatments: 0 fractional worksPeroxisome Proliferator-…0Peroxisome Proliferator-Activated Receptors: 0 fractional worksinterferon and immune responses: 0 fractional worksAldose Reductase and Taurine: 0 fractional worksCancer, Hypoxia, and Metabolism: 0 fractional worksVirus-based gene therapy research: 0 fractional works
EpidemiologyOncologyHepatologyBiotechnology6 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Liver Disease Diagnosis and Treatment Epidemiology 1 works
  2. 2 Drug Transport and Resistance Mechanisms Oncology 1 works
  3. 3 Liver Diseases and Immunity Hepatology 0 works
  4. 4 Cancer Research and Treatments Biotechnology 0 works
  5. 5 Pediatric Hepatobiliary Diseases and Treatments Surgery 0 works
  6. 6 Peroxisome Proliferator-Activated Receptors Molecular Biology 0 works
  7. 7 interferon and immune responses Immunology 0 works
  8. 8 Aldose Reductase and Taurine Cell Biology 0 works
  9. 9 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  10. 10 Virus-based gene therapy research Genetics 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available50.5%not open49.5%

World: 28% of research is openly available.

with international co-authors40.3%domestic only59.7%

World: 19% is written across borders.

How has CymaBay Therapeutics (United States)'s research output changed?

Output in 2018–2022 was 7% higher than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Newark

All research institutions in Newark

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.